Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model

Journal of Hepatology

Volumn 38, Issue 3, 2003, Pages 328-334

  Le Guerhier, Franck ^a   Thermet, Alexandre ^a   Guerret, Sylvianne ^b   Chevallier, Michèle ^c   Jamard, Catherine ^a   Gibbs, Craig S ^d   Trépo, Christian ^a   Cova, Lucyna ^a   Zoulim, Fabien ^a  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Department of Pathology   (France)

^d GILEAD SCIENCES   (United States)

Author keywords

Adefovir; DNA vaccine; Duck HBV infection model; Hepatitis B

Indexed keywords

ADEFOVIR; DNA; DNA VACCINE; ENVELOPE PROTEIN; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; AUTOPSY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG WITHDRAWAL; DUCK; HEPATITIS B; HEPATITIS B VIRUS; IMMUNIZATION; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION;

EID: 0037338003     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00425-7     Document Type: Article

References (34)

1. Perrillo RP, Schiff ER, Davis GL, Bodenheimer Jr HC, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323(5):295-301.
2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
3. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
4. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Harm HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256-1263.
5. Zoulim F. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res 1999;44(1):1-30.
6. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32(1):129-134.
7. Xiong XF, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28(6):1669-1673.
8. Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999;57(12):1351-1359.
9. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103(12):1635-1640.
10. Xiong XF, Yang HL, Westland CE, Zou RM, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000;31(1):219-224.
11. Seigneres B, Aguesse-Germon S, Pichoud C, Vuillermoz I, Jamard C, Trepo C, Zoulim F. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol 2001;34(1):114-122.
12. Heijtink RA, De Wilde GA, Kruining J, Berk L, Balzarini J, De Clercq E, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993;21(2):141-153.
13. Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 1998;42:3130-3135.
14. Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O, Zoulim F. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002;46(2):425-433.
15. Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J, et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 2001;45(10):2740-2745.
16. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29(6):1863-1869.
17. Calio R, Villani N, Balestra E, Sesa F, Holy A, Balzarini J, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994;23(1):77-89.
18. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [see comments]. J Clin Invest 1998;102(5):968-975.
19. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33(4):963-971.
20. Davis HL, Schirmbeck R, Reimann J, Whalen RG. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 1995;6(11):1447-1456.
21. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995;92(12):5307-5311.
22. Schirmbeck R, Bohm W, Ando K, Chisari F, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol 1995;69:5929-5934.
23. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996;93(14):7213-7218.
24. Prince AM, Whalen R, Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 1997;15(8):916-919.
25. Rollier C, Sunyach C, Barraud L, Madani N, Jamard C, Trepo C, Cova L. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999;116(3):658-665.
26. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, et al. Induction of antigen-specific CD8+ T cells, T helper cells and protective levels of antibody of humans by particle-mediated administration of hepatitis B virus DNA vaccine. Vaccine 2001;19:764-778.
27. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996;93(22):12496-12501.
28. Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, et al. Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000;44(1):111-122.
29. Chassot S, Lambert V, Kay A, Godinot C, Trépo C, Cova L. Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning. Virology 1994;200:72-78.
30. Zoulim F, Dannaoui E, Borel C, Hantz O, Lin T-S, Liu S-H, et al. 2′,3′-dideoxy-b-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother 1996;40:448-453.
31. Jilbert AR, Wu TT, England JM, De La M Hall P, Carp NZ, O'Connell AP, Mason WS. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 1992;66:1377-1388.
32. Chassot S, Lambert V, Kay A, Godinot C, Roux B, Trépo C, Cova L. Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides. Virology 1993;192:217-223.
33. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47(2):331-385.
34. Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1998;8(2):181-184.